FDA Approves Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma
April 4th 2022Axicabtagene ciloleucel (Yescarta) approved for patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy.
Read More
Data Show Rivaroxaban Lowers Severe Vascular Event Risk in Patients With PAD
April 3rd 2022Results of the phase 3 VOYAGER PAD clinical trial show rivaroxaban (Xarelto; Janssen Pharmaceutical Companies) plus aspirin lowers severe vascular events in patients with peripheral arterial disease after lower-extremity revascularization.
Read More
Keynote Speakers at 2019 Directions in Oncology Pharmacy Promote Quality Improvement
December 30th 2019Evelyn Handel, PharmD, BCPS, BCOP, director of drugs & biologics programs at the National Comprehensive Cancer Network, presented the keynote address, which was developed in collaboration with Emily Mackler, PharmD, BCOP, of the Michigan Oncology Quality Consortium in Ann Arbor.
Read More